Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development
by Philip D. Harvey, PhD; Joan Busner, PhD; Gahan Pandina, [...]
Implications of Pediatric Initiatives on CNS Drug Development for All Ages—2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development
by Gahan Pandina, PhD; Joan Busner, PhD; Joseph P. Horrigan, [...]
Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development
by Joan Busner, PhD; Gahan Pandina, PhD; Simon Day, PhD; Atul [...]
Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs
by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, [...]
CNS Summit 2016 Abstracts of Poster Presentations
Innov Clin Neurosci. 2017;14(1–2)3–23. A MESSAGE FROM THE EDITOR Dear [...]
Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders
by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS—David [...]
Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium
by Jared W. Young, PhD; William Z. Potter, MD, PhD; [...]
Lessons Learned and Potentials for Improvement in CNS Drug Development: ISCTM Section on Designing the Right Series of Experiments
by Steven T. Szabo, MD, PhD; Bruce J. Kinon, MD; [...]
Taking Personalized Medicine Seriously: Biomarker Approaches in Phase IIb/III Studies in Major Depression and Schizophrenia
by Harald Murck, MD, PhD; Thomas Laughren, MD; Femke Lamers, [...]
How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?
by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE [...]